SILO PHARMA, INC. Investment Income, Interest and Dividend
SILO PHARMA, INC. (SILO) reported Investment Income, Interest and Dividend of $39.16 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterestAndDividend · last filed 2026-08-13
- SILO PHARMA, INC. investment income, interest and dividend for the quarter ending 2026-06-30 was $39.16K, a 12.83% decline year-over-year.
- SILO PHARMA, INC. investment income, interest and dividend for the quarter ending 2026-03-31 was $38.72K, a 37.38% decline year-over-year.
- SILO PHARMA, INC. investment income, interest and dividend for the quarter ending 2025-12-31 was $42.56K, a 48.72% decline year-over-year.
- SILO PHARMA, INC. investment income, interest and dividend for the quarter ending 2025-09-30 was $44.60K, a 47.49% decline year-over-year.
- SILO PHARMA, INC. investment income, interest and dividend for fiscal 2023 was $398.53K, a 448.66% increase from fiscal 2022.
- SILO PHARMA, INC. investment income, interest and dividend for fiscal 2022 was $72.64K.
| Period end | Investment Income, Interest and Dividend 3 month | Investment Income, Interest and Dividend 6 month | Investment Income, Interest and Dividend 9 month | Investment Income, Interest and Dividend 12 month |
|---|---|---|---|---|
| 2026-06-30 | $39.16K 10-Q · filed 2026-08-13 | $77.87K 10-Q · filed 2026-08-13 | $120.44K derived: sum of 3 quarters · filed 2026-08-13 | $165.04K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $38.72K 10-Q · filed 2026-05-14 | $81.28K derived: sum of 2 quarters · filed 2026-05-14 | $125.89K derived: sum of 3 quarters · filed 2026-05-14 | $170.80K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $42.56K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-14 | $87.17K derived: sum of 2 quarters · filed 2026-04-14 | $132.08K derived: sum of 3 quarters · filed 2026-08-13 | $193.91K POS AM · filed 2026-04-14 |
| 2025-09-30 | $44.60K 10-Q · filed 2025-11-13 | $89.52K derived: sum of 2 quarters · filed 2026-08-13 | $151.35K 10-Q · filed 2025-11-13 | $234.35K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $44.92K 10-Q · filed 2026-08-13 | $106.75K 10-Q · filed 2026-08-13 | $189.75K derived: sum of 3 quarters · filed 2026-08-13 | $274.69K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $61.83K 10-Q · filed 2026-05-14 | $144.83K derived: sum of 2 quarters · filed 2026-05-14 | $229.77K derived: sum of 3 quarters · filed 2026-05-14 | $306.82K derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $83.01K derived: POS AM 12 month − 10-Q 9 month · filed 2026-04-14 | $167.95K derived: sum of 2 quarters · filed 2026-04-14 | $244.99K derived: sum of 3 quarters · filed 2026-04-14 | $333.17K POS AM · filed 2026-04-14 |
| 2024-09-30 | $84.94K 10-Q · filed 2025-11-13 | $161.98K derived: sum of 2 quarters · filed 2025-11-13 | $250.16K 10-Q · filed 2025-11-13 | $358.54K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $77.04K 10-Q · filed 2025-08-13 | $165.22K 10-Q · filed 2025-08-13 | $273.60K derived: sum of 3 quarters · filed 2025-08-13 | $389.78K derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $88.18K 10-Q · filed 2025-05-09 | $196.56K derived: sum of 2 quarters · filed 2025-05-09 | $312.74K derived: sum of 3 quarters · filed 2025-05-09 | $422.32K derived: sum of 4 quarters · filed 2025-05-09 |
| 2023-12-31 | $108.38K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-28 | $224.56K derived: sum of 2 quarters · filed 2025-03-28 | $334.14K derived: sum of 3 quarters · filed 2025-03-28 | $398.53K 10-K · filed 2025-03-28 |
| 2023-09-30 | $116.18K 10-Q · filed 2024-11-12 | $225.76K derived: sum of 2 quarters · filed 2024-11-12 | $290.15K 10-Q · filed 2024-11-12 | $361.01K derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $109.58K 10-Q · filed 2024-08-13 | $173.97K 10-Q · filed 2024-08-13 | $244.84K derived: sum of 3 quarters · filed 2024-08-13 | $245.82K derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $64.39K 10-Q · filed 2024-05-13 | $135.25K derived: sum of 2 quarters · filed 2024-05-13 | $136.23K derived: sum of 3 quarters · filed 2024-05-13 | $136.61K derived: sum of 4 quarters · filed 2024-05-13 |
| 2022-12-31 | $70.86K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-25 | $71.84K derived: sum of 2 quarters · filed 2024-03-25 | $72.22K derived: sum of 3 quarters · filed 2024-03-25 | $72.64K 10-K · filed 2024-03-25 |
| 2022-09-30 | $981.00 10-Q · filed 2023-11-13 | $1.36K derived: sum of 2 quarters · filed 2023-11-13 | $1.77K 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $377.00 10-Q · filed 2023-08-11 | $792.00 10-Q · filed 2023-08-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |